Your browser doesn't support javascript.
loading
Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy.
Emran, Abdullah Al; Chatterjee, Aniruddha; Rodger, Euan J; Tiffen, Jessamy C; Gallagher, Stuart J; Eccles, Michael R; Hersey, Peter.
Affiliation
  • Emran AA; Melanoma Immunology and Oncology Group, The Centenary Institute, University of Sydney, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia; These authors contributed equally.
  • Chatterjee A; Department of Pathology, Dunedin School of Medicine, University of Otago, 270 Great King Street, Dunedin 9054, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Level, 3A Symonds Street, Auckland, New Zealand; These authors contributed equally.
  • Rodger EJ; Department of Pathology, Dunedin School of Medicine, University of Otago, 270 Great King Street, Dunedin 9054, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Level, 3A Symonds Street, Auckland, New Zealand.
  • Tiffen JC; Melanoma Immunology and Oncology Group, The Centenary Institute, University of Sydney, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia.
  • Gallagher SJ; Melanoma Immunology and Oncology Group, The Centenary Institute, University of Sydney, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia.
  • Eccles MR; Department of Pathology, Dunedin School of Medicine, University of Otago, 270 Great King Street, Dunedin 9054, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, Level, 3A Symonds Street, Auckland, New Zealand; Senior author.
  • Hersey P; Melanoma Immunology and Oncology Group, The Centenary Institute, University of Sydney, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia; Senior author. Electronic address: p.hersey@centenary.org.au.
Trends Immunol ; 40(4): 328-344, 2019 04.
Article in En | MEDLINE | ID: mdl-30853334
Methylation of DNA at CpG sites is the most common and stable of epigenetic changes in cancer. Hypermethylation acts to limit immune checkpoint blockade immunotherapy by inhibiting endogenous interferon responses needed for recognition of cancer cells. By contrast, global hypomethylation results in the expression of programmed death ligand 1 (PD-L1) and inhibitory cytokines, accompanied by epithelial-mesenchymal changes that can contribute to immunosuppression. The drivers of these contrasting methylation states are not well understood. DNA methylation also plays a key role in cytotoxic T cell 'exhaustion' associated with tumor progression. We present an updated exploratory analysis of how DNA methylation may define patient subgroups and can be targeted to develop tailored treatment combinations to help improve patient outcomes.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Drug Resistance, Neoplasm / DNA Methylation / Enhancer of Zeste Homolog 2 Protein / Immunotherapy / Melanoma Limits: Humans Language: En Journal: Trends Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2019 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Drug Resistance, Neoplasm / DNA Methylation / Enhancer of Zeste Homolog 2 Protein / Immunotherapy / Melanoma Limits: Humans Language: En Journal: Trends Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2019 Type: Article